Timothy Illidge, MD, PhD of @OfficialUoM provides analysis of brentuximab vedotin plus CHP (A+CHP) in the frontline treatment of patients with CD30+ peripheral T-Cell lymphomas (ECHELON-2).
Analysis of Brentuximab Vedotin Plus CHP (A+CHP) #ASH19 @OfficialUoM
